Revlixen 10 mg (Lenalidomide) Capsule

Revlixen 10 mg Lenalidomide Capsule packaging by Everest Pharma - Supplied by Onco Solution

Revlixen 10 mg (Lenalidomide) Capsule

Product ID: 13988

Introduction

Revlixen 10 mg Capsule contains Lenalidomide, an immunomodulatory drug primarily used in the treatment of various hematological cancers. It is known for its potent anti-cancer, antiangiogenic, and immunomodulatory effects. Revlixen is manufactured by Everest Pharmaceuticals Ltd and is supplied globally by Onco Solution — your trusted oncology medicine partner.

Key Benefits

  • Highly effective in treating multiple myeloma (MM) and myelodysplastic syndromes (MDS)
  • Extends maintenance therapy for MM patients post-stem cell transplant
  • Suitable for relapsed/refractory mantle cell lymphoma (MCL)
  • Effective in combination therapy for follicular lymphoma (FL) and marginal zone lymphoma (MZL)
  • Manufactured under stringent GMP compliance

Indications

Revlixen 10 mg is indicated for:

  • Multiple Myeloma (MM): In combination with Dexamethasone or as maintenance therapy after autologous hematopoietic stem cell transplantation (auto-HSCT).
  • Myelodysplastic Syndromes (MDS): For transfusion-dependent anemia associated with 5q cytogenetic abnormalities.
  • Mantle Cell Lymphoma (MCL): For patients with relapsed or progressed disease after two prior therapies.
  • Follicular Lymphoma (FL) & Marginal Zone Lymphoma (MZL): In combination with Rituximab for previously treated cases.

Dosage & Administration

Maintenance Therapy Post auto-HSCT:

  • Start with 10 mg once daily on Days 1-28 in 28-day cycles.
  • If tolerated, increase to 15 mg after 3 cycles.

For MDS:

  • 10 mg daily until disease progression or toxicity.

Administration Guidelines:

  • Swallow the capsule whole with water.
  • Take at the same time daily, with or without food.

Pharmacology

Lenalidomide works by targeting cereblon, a protein in the ubiquitin ligase complex. This leads to degradation of transcription factors (Ikaros, Aiolos), modulating the immune response and exerting anti-tumor effects. It inhibits cancer cell proliferation, induces apoptosis, and enhances NK and T-cell activity. It also reduces inflammatory cytokines like TNF-α and IL-6.

Pharmacokinetics:

  • Absorption: Rapid; peak plasma levels in 0.5–6 hours
  • Distribution: ~30% plasma protein binding
  • Metabolism: Minimal metabolism; largely excreted unchanged
  • Elimination: Primarily renal; ~82% via urine within 24 hours

Drug Interactions

  • Digoxin: May increase Digoxin levels; monitor plasma levels.
  • Warfarin: No significant interactions observed, but monitor PT/INR.
  • Thrombosis Risk: Use with caution alongside erythropoietic or estrogenic agents.

Contraindications

  • Pregnancy: Causes severe fetal harm; contraindicated in pregnant females.
  • Severe Hypersensitivity: Includes reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

Side Effects

  • Embryo-fetal toxicity
  • Blood disorders: Neutropenia, thrombocytopenia
  • Risk of thromboembolism (DVT, PE)
  • Secondary malignancies
  • Hepatotoxicity
  • Severe skin reactions (SJS, TEN, DRESS)
  • Tumor lysis syndrome
  • Thyroid dysfunction

Special Populations

  • Pediatrics: Not established for patients under 18 years
  • Lactation: Unknown if excreted in breast milk. Avoid breastfeeding.

Precautions & Warnings

  • REMS Program: Only available through Revlixen REMS for safety.
  • Hematologic Monitoring: Frequent CBC tests required during treatment.
  • Thromboprophylaxis: Recommended due to high VTE/ATE risks.
  • Liver Monitoring: Monitor liver enzymes during therapy.
  • Stem Cell Mobilization: Early referral for transplant planning is advised.

Overdose

There is no specific antidote for Lenalidomide overdose. Symptomatic management and supportive care are recommended.

Storage Conditions

  • Store below 30°C
  • Protect from moisture and light
  • Keep out of reach of children

Manufacturer & Supplier Info

Manufacturer: Everest Pharmaceuticals Ltd
Global Supplier: Onco Solution – A Leading Worldwide Oncology Medicine Supplier

Conclusion

Revlixen 10 mg (Lenalidomide) Capsule is a proven, globally trusted oncology medication for treating hematologic malignancies. Onco Solution ensures consistent worldwide access to high-quality oncology treatments like Revlixen. Contact us for bulk supply or product queries.

error: Content is protected !!
Revlixen 10 mg Lenalidomide Capsule packaging by Everest Pharma - Supplied by Onco Solution

Request quote Now